TY - JOUR
T1 - Diagnostic accuracy of contrast-enhanced ultrasound for characterization of kidney lesions in patients with and without chronic kidney disease
AU - Chang, Emily Hueywen
AU - Chong, Wui Kheong
AU - Kasoji, Sandeep Kumar
AU - Fielding, Julia Rose
AU - Altun, Ersan
AU - Mullin, Lee B.
AU - Kim, Jung In
AU - Fine, Jason Peter
AU - Dayton, Paul Alexander
AU - Rathmell, Wendy Kimryn
N1 - Funding Information:
Support for this work was provided by NC TraCS at the University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center Core Grant and NIH grant K24CA172355. No specific roles were fulfilled by any funding agency.
Publisher Copyright:
© 2017 The Author(s).
PY - 2017/8/9
Y1 - 2017/8/9
N2 - Background: Patients with chronic kidney disease are at increased risk of cystic kidney disease that requires imaging monitoring in many cases. However, these same patients often have contraindications to contrast-enhanced computed tomography and magnetic resonance imaging. This study evaluates the accuracy of contrast-enhanced ultrasound (CEUS), which is safe for patients with chronic kidney disease, for the characterization of kidney lesions in patients with and without chronic kidney disease. Methods: We performed CEUS on 44 patients, both with and without chronic kidney disease, with indeterminate or suspicious kidney lesions (both cystic and solid). Two masked radiologists categorized lesions using CEUS images according to contrast-enhanced ultrasound adapted criteria. CEUS designation was compared to histology or follow-up imaging in cases without available tissue in all patients and the subset with chronic kidney disease to determine sensitivity, specificity and overall accuracy. Results: Across all patients, CEUS had a sensitivity of 96% (95% CI: 84%, 99%) and specificity of 50% (95% CI: 32%, 68%) for detecting malignancy. Among patients with chronic kidney disease, CEUS sensitivity was 90% (95% CI: 56%, 98%), and specificity was 55% (95% CI: 36%, 73%). Conclusions: CEUS has high sensitivity for identifying malignancy of kidney lesions. However, because specificity is low, modifications to the classification scheme for contrast-enhanced ultrasound could be considered as a way to improve contrast-enhanced ultrasound specificity and thus overall performance. Due to its sensitivity, among patients with chronic kidney disease or other contrast contraindications, CEUS has potential as an imaging test to rule out malignancy. Trial registration: This trial was registered in clinicaltrials.gov, NCT01751529.
AB - Background: Patients with chronic kidney disease are at increased risk of cystic kidney disease that requires imaging monitoring in many cases. However, these same patients often have contraindications to contrast-enhanced computed tomography and magnetic resonance imaging. This study evaluates the accuracy of contrast-enhanced ultrasound (CEUS), which is safe for patients with chronic kidney disease, for the characterization of kidney lesions in patients with and without chronic kidney disease. Methods: We performed CEUS on 44 patients, both with and without chronic kidney disease, with indeterminate or suspicious kidney lesions (both cystic and solid). Two masked radiologists categorized lesions using CEUS images according to contrast-enhanced ultrasound adapted criteria. CEUS designation was compared to histology or follow-up imaging in cases without available tissue in all patients and the subset with chronic kidney disease to determine sensitivity, specificity and overall accuracy. Results: Across all patients, CEUS had a sensitivity of 96% (95% CI: 84%, 99%) and specificity of 50% (95% CI: 32%, 68%) for detecting malignancy. Among patients with chronic kidney disease, CEUS sensitivity was 90% (95% CI: 56%, 98%), and specificity was 55% (95% CI: 36%, 73%). Conclusions: CEUS has high sensitivity for identifying malignancy of kidney lesions. However, because specificity is low, modifications to the classification scheme for contrast-enhanced ultrasound could be considered as a way to improve contrast-enhanced ultrasound specificity and thus overall performance. Due to its sensitivity, among patients with chronic kidney disease or other contrast contraindications, CEUS has potential as an imaging test to rule out malignancy. Trial registration: This trial was registered in clinicaltrials.gov, NCT01751529.
KW - Chronic kidney disease
KW - Contrast
KW - Contrast-enhanced ultrasound
KW - Kidney
KW - Kidney lesion
KW - Ultrasound
UR - http://www.scopus.com/inward/record.url?scp=85027281800&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85027281800&partnerID=8YFLogxK
U2 - 10.1186/s12882-017-0681-8
DO - 10.1186/s12882-017-0681-8
M3 - Article
C2 - 28793871
AN - SCOPUS:85027281800
SN - 1471-2369
VL - 18
JO - BMC nephrology
JF - BMC nephrology
IS - 1
M1 - 266
ER -